Evidence map›Paper›PMID 42376811›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026

Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab.

Erin L MacMillan, Bretta Russell-Schulz, Glaynel Alejo, Christopher Harp, Briana Cameron, Ryan Winger, Sherman Jia, Ann Herman, Jasmyne Kassam, Michael Waine and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02688985 (An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02688985 phase3completednot on this map

An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis

TypeinterventionalSponsorGenentech, Inc.Ran2016 to 2023Enrolled131ConditionsRelapsing Multiple Sclerorsis, Multiple Sclerosis, Primary ProgressiveArmsOcrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Erin L MacMillanDepartment of Radiology, UBC MRI Research Centre, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada; Department of Radiology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-8515-5858
Bretta Russell-SchulzDepartment of Radiology, UBC MRI Research Centre, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Glaynel AlejoDepartment of Radiology, UBC MRI Research Centre, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Christopher HarpGenentech, Inc., A Member of the Roche Group, South San Francisco, CA, USA.
Briana CameronGenentech, Inc., A Member of the Roche Group, South San Francisco, CA, USA.
Ryan WingerGenentech, Inc., A Member of the Roche Group, South San Francisco, CA, USA.
Sherman JiaGenentech, Inc., A Member of the Roche Group, South San Francisco, CA, USA.
Ann HermanGenentech, Inc., A Member of the Roche Group, South San Francisco, CA, USA.
Jasmyne KassamDivision of Neurology, Department of Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Michael WaineDivision of Neurology, Department of Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Irene M VavasourDepartment of Radiology, UBC MRI Research Centre, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada; Department of Radiology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0001-9286-0953
Helen CrossDivision of Neurology, Department of Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Roger TamDepartment of Radiology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada; School of Biomedical Engineering, The University of British Columbia, Vancouver, BC, Canada.
Anthony L TraboulseeDivision of Neurology, Department of Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Robert CarruthersDivision of Neurology, Department of Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0001-7085-1001
Shannon H KolindDepartment of Radiology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada; Division of Neurology, Department of Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0003-1362-1968

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMagnetic resonance spectroscopy (MRS) offers non-invasive assessments of neuron-oligodendrocyte coupling and neuroinflammation to monitor treatment response in multiple sclerosis (MS).

objectiveTo track changes in N-acetylaspartate and myo-inositol in relapsing MS (RMS) and primary progressive MS (PPMS) patients treated with ocrelizumab over 2 years.

methodsSingle-voxel MRS at 3T was acquired at baseline in 10 healthy controls (HCs), and weeks 0, 12, 24, 52, and 96 in MS participants at a single center.

resultsBaseline myo-inositol was higher in PPMS than RMS (

conclusionOcrelizumab treatment is associated with declining myo-inositol levels measured by MRS in both RMS and PPMS. Myo-inositol offers a unique biomarker to track resolution of gliosis and reactive microglia with treatment. Furthermore, the relationship between a higher concentration of myo-inositol and greater disability across both MS subtypes at baseline supports the presence of "smouldering inflammation" as a disease process across the spectrum of MS. CLINICAL TRIAL: Sub-study of the Ocrelizumab Biomarker Outcome Evaluation (OBOE; ML29966) trial: https://clinicaltrials.gov/study/NCT02688985.

Indexed as

longitudinal treatment trackingmagnetic resonance spectroscopymyo-InositolN-acetylaspartateprimary progressive multiple sclerosisRelapsing multiple sclerosis

Identifiers

PMID42376811
PMCPMC13646435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.